Cargando…

Beyond finding druggable targets and tumor mutational burden: to measure heterogeneity by ctDNA

Detalles Bibliográficos
Autores principales:	Liu, Zhichao, He, Jianxing, Liang, Wenhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327335/ https://www.ncbi.nlm.nih.gov/pubmed/32617343 http://dx.doi.org/10.21037/atm.2020.01.86

Ejemplares similares

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
por: Keller, Laura, et al.
Publicado: (2020)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

The feasibility of using mutation detection in ctDNA to assess tumor dynamics
por: Yi, Xin, et al.
Publicado: (2017)

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
por: Zheng, Yang, et al.
Publicado: (2021)

Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
por: Fitzgerald, Sandra, et al.
Publicado: (2023)

ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA
por: Huebner, Ariana, et al.
Publicado: (2023)

Tumor Heterogeneity and Drug Resistance Mutations Using ctDNA in Metastatic EGFR Mutation-Positive Lung Adenocarcinoma: A Case Report
por: Sun, Jinghua, et al.
Publicado: (2022)

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer
por: Bai, Fei, et al.
Publicado: (2023)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer
por: Lyu, Mengyuan, et al.
Publicado: (2019)

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
por: Stecklein, Shane R., et al.
Publicado: (2023)

Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
por: Duffy, Michael J., et al.
Publicado: (2022)

Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA)
por: Liang, Wenhua, et al.
Publicado: (2019)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay
por: Lyu, Nana, et al.
Publicado: (2020)

The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
por: Sobczuk, Paweł, et al.
Publicado: (2022)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

Current and Future Clinical Applications of ctDNA in Immuno-Oncology
por: Stadler, Julia-Christina, et al.
Publicado: (2022)

Regulatory implications of ctDNA in immuno-oncology for solid tumors
por: Vellanki, Paz J, et al.
Publicado: (2023)

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review
por: Wang, Wenwen, et al.
Publicado: (2023)

Combinatorial assessment of ctDNA release and mutational burden predicts anti‐PD(L)1 therapy outcome in nonsmall‐cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2020)

Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models
por: Sauer, Carolin M, et al.
Publicado: (2022)

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)

ctDNA Detection Based on DNA Clutch Probes and Strand Exchange Mechanism
por: Chang, Huan, et al.
Publicado: (2018)

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
por: Vidal, J, et al.
Publicado: (2017)

Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL
por: Liu, Hui, et al.
Publicado: (2020)

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers
por: Xie, Jianjiang, et al.
Publicado: (2023)

Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2023)

Complex Patterns of Genomic Heterogeneity Identified in 42 Tumor Samples and ctDNA of a Pulmonary Atypical Carcinoid Patient
por: Robb, Tamsin J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8sd3t9d4o2ti53gvf8894gnkrq